Enveric Biosciences
ENVB
1 hedge funds and large institutions have $1.76M invested in Enveric Biosciences in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
5,594% more capital invested
Capital invested by funds: $31K → $1.76M (+$1.73M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$11K |
| 2 |
CF
Centaurus Financial
Anaheim,
California
|
-$10K |
| 3 |
JA
JOYN Advisors
Atlanta,
Georgia
|
-$1K |
ENVB Hedge Fund Activity: Q3 2018 in Review
1 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q3 2018, worth a combined $1.76M — up 5,594% from $31K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ENVB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $1.29M. The largest seller was Jane Street, cutting an estimated $11K.
- 1 institutional investor held Enveric Biosciences (ENVB) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $1.76M of Enveric Biosciences stock for Q3 2018, up 5,594% quarter-over-quarter.
- 1 fund opened new Enveric Biosciences positions in Q3 2018 and 0 closed out, a net change of +1 holder.
- The largest Enveric Biosciences buyer in Q3 2018 was Hudson Bay Capital Management, an estimated $1.29M added.
- The largest Enveric Biosciences seller in Q3 2018 was Jane Street, an estimated $11K sold.
Based on aggregated 13F filings for Q3 2018.